Systemic Mastocytosis clinical trials at UCSF
1 in progress, 0 open to eligible people
Showing trials for
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Sorry, in progress, not accepting new patients
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an expansion phase. All active patients (from both dose-escalation and expansion phases) will then transition into an extension phase.
San Francisco, California and other locations
Last updated: